報價延遲最少15分鐘:2025/11/18 09:13 EST
盤前時段
|
||||
|
13 
|
|
|
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
--
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-3.00/-2.83
|
|
企業價值
1.11B
|
| 資產負債 |
|
每股賬面淨值
2.42
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
43.27M
|
|
每股收益
0.51
|
|
同行比較
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
報價延遲最少15分鐘：2025/11/18 09:13 EST
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| EyePoint Pharmaceuticals Inc is a pharmaceutical company. It is engaged in developing and commercializing ophthalmic products for the treatment of eye diseases. The company has developed FDA-approved sustained-release treatments in ophthalmology. Its pre-clinical development program is focused on using its core Durasert E and Verisome technology platforms to deliver drugs to treat wet age-related macular degeneration, glaucoma, osteoarthritis, and other diseases. Geographically, the firm has operational footprints in the U.S., China, and the UK. It generates a majority of its revenue from the U.S. |
